MacroGenics develops antibody-based cancer therapies using multiple proprietary technology platforms, including bispecific DART molecules and antibody-drug conjugates. Several of its candidates employ novel topoisomerase I inhibitor payloads delivered via ADCs targeting antigens such as B7-H3 and ADAM9 on solid tumors. The company has formed collaborations with major pharmaceutical partners and previously contributed technology to approved biologic products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 6.9 | — | -36.3 | — |
| Q3 2025 | 72.8 | — | 16.8 | — |
| Q4 2025 | 41.2 | — | -14.2 | — |
| Q1 2026 | 20.8 | — | -36.8 | — |
| Q2 2026 | 32.8 | 378% | 19.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Jones Ventures INTL Acquisition1 Corp (JONE), HMH Holding Inc. (HMH), Larimar Therapeutics, Inc. (LRMR), Alector, Inc. (ALEC), Willow Lane Acquisition Corp. II (WLII), Citizens Community Bancorp, Inc. (CZWI)